Mperia Therapeutics' Series A Round

Mperia Therapeutics raised a round of funding on September 13, 2016. Investors include AmorChem.

Mperia Therapeutics is a biotech company focusing on macrophage-based immunotherapy with the use of novel ligand derivatives with high affinity to the CD36 cell surface receptor. Mperia's immunotherap…

Articles about Mperia Therapeutics' Series A Round: